PRINCETON, N.J., Jan. 24 /PRNewswire/ -- Pharmasset is pleased to announce the appointments of M. Michelle Berrey, MD, MPH as Chief Medical Officer and William T. Symonds, PharmD as Vice President, Clinical Pharmacology. Dr. Berrey joins us from GlaxoSmithKline, where she most recently served as Vice President, Viral Diseases, Clinical Pharmacology & Discovery Medicine. Dr. Symonds also joins us from GlaxoSmithKline, where he most recently served as Director, Antiviral Clinical Pharmacology & Discovery Medicine.
Dr. Berrey’s experience includes the design, early development, medical governance, clinical strategy and product life cycle management for antiviral products, and she has simultaneously managed multiple clinical trials across all phases of development. Dr. Berrey was most recently responsible for the early development and clinical strategy of Phase I-IIa studies for new targets against HIV, hepatitis viruses and hepatic fibrosis at GlaxoSmithKline. Dr. Berrey received a Master of Public Health from Emory University, and she received her M.D. from the Medical College of Georgia. She completed her Internship and Residency in Internal Medicine at the University of North Carolina, Chapel Hill, and she was a Senior Fellow in Infectious Disease Medicine at the University of Washington, Seattle, where she conducted research in HIV transmission and acute HIV infection.
Dr. Symonds has clinical pharmacology experience in anti-infective and antiviral drug development, including international drug development and medical project management from Phases I to IV. He contributed to regulatory filings for several marketed antiviral compounds and was most recently involved in the early phase development of several antiviral programs.
Dr. Symonds received his Doctorate of Pharmacy from Campbell University in North Carolina, and he completed a Fellowship in Clinical Pharmacokinetics focusing on anti-infective pharmacology at the Clinical Pharmacokinetics Laboratory at Millard Fillmore Hospital in Buffalo, New York.
About Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset’s primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Contact: Alan Roemer Vice President, Investor Relations & Corporate Communications alan.roemer@pharmasset.com Office: (609) 613-4125
Statements in this company press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure of our clinical programs to perform as expected, the company’s ability to attract and retain qualified personnel to conduct the required clinical trials for our clinical programs, the status of the company’s HCV collaboration with Roche, the company’s future capital needs to fund the development programs, the company’s ability to obtain additional financing, the company’s ability to obtain required regulatory approvals for our clinical programs, the development of competitive products by others, the existence of third-party patent rights, and other risks inherent in discovery and development stage programs at a biotechnology company. The actual results for our programs may differ materially from those anticipated in this company press release. The company disclaims any obligation to update the statements contained in this company press release.
Pharmasset
CONTACT: Alan Roemer, Vice President, Investor Relations & CorporateCommunications of Pharmasset, +1-609-613-4125, oralan.roemer@pharmasset.com
Web site: http://www.pharmasset.com/
